【medical-news】【资讯翻译】使用Corevalve与Sapien两种商业TAVI瓣临床结局相同
发布于 2013-01-21 · 浏览 1548 · IP 上海上海
这个帖子发布于 12 年零 114 天前，其中的信息可能已发生改变或有所发展。
认领翻译的战友请跟帖注明“认领本文翻译，若48小时内未完成，请其他战友认领！
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看：
【公告】动态版重启资讯翻译计划：我为人人，人人为我，共同提高 翻译时请把不确定的地方用红色字体标注，
寻找最近的翻译贴请查看：
点击进入
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
翻译三天未加分找 【版务】加分申诉点击
举报和合并加分专贴
【公告】版务管理之【举报和合并加分专贴】仅限于10分以下战友
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分。
原文链接：
http://www.medscape.com/viewarticle/777854
Equivalent Outcomes With Corevalve and Sapien Transcatheter Aortic Valves
MILAN, Italy — A head-to-head comparison of the CoreValve (Medtronic, Minneapolis, MN) and Sapien(Edwards, Irvine, CA) transcatheter aortic-valve implantation (TAVI) systems suggests there is no major difference between the two commercially available devices. At 30 days, there was no difference in the rate of all-cause mortality, cardiovascular mortality, MI, stroke, or device success, as well as no major difference in the rate of major vascular complications or life-threatening bleeding events.
In addition, there was no major difference in the rate of all-cause or cardiovascular mortality at one year.
The Medtronic CoreValve was associated with a higher rate of permanent pacemaker implantation, with 22.5% of patients requiring a pacemaker compared with 5.9% of patients treated with the Edwards Sapien/Sapien XT devices (hazard ratio [HR] 4.6; p<0.001).
"Overall, our results are encouraging, showing no difference between commercially available valve types except for a greater need for a [permanent pacemaker] PPM with the [Medtronic CoreValve], but clearly longer-term follow-up in the setting of an adequately powered randomized clinical trial is needed," state Dr Alaide Chieffo (San Raffaele Scientific Institute, Milan, Italy) and colleagues in their report, published online January 16, 2013 in the Journal of the American College of Cardiology.
Speaking with heart wire , Dr J Jeffrey Marshall (Northeast Georgia Heart Center, Gainesville), the president of the Society of Cardiovascular Angiography and Interventions, said the findings are in line with expectations, with clinicians well aware that the CoreValve, because of its self-expanding design, is associated with an increased risk of a need for a permanent pacemaker.
"Any time you have to have another procedure performed, it's not something you'd prefer, but it doesn't occur in a huge number of patients," said Marshall. "The need for a permanent pacemaker implantation is not something that's associated with a lot of complications in and of itself, so it's not that great an issue, although there is an extra cost, obviously."
Marshall noted that the incidence of aortic regurgitation was equal with both valves, a finding he said was reassuring, considering that previous trials suggested there might be differences between the valves in terms of aortic insufficiency following the procedure.
The PRAGMATIC Plus Initiative
The study, known as the PRAGMATIC Plus Initiative, included data from four experienced European centers. In total, 793 patients underwent TAVI, including 453 patients treated with the Medtronic CoreValve and 340 patients treated with the Edwards Sapien/Sapien XT devices. The 18-F sheath-compatible CoreValve was used in all but five cases (in these five cases the 21-F device was used) and the Sapien system used 22-/24-F sheaths until 2010, when the Sapien XT device offered the option of 18-/19-F sheath sizes. The average patient age was 82 years.
As noted, there was no significant difference in the 30-day and one-year clinical outcomes between the two TAVI systems. Because there were differences in the baseline characteristics of patients, the analysis was based on 204 propensity-score-matched patients.
Clinical Outcomes in the Propensity-Matched Patients
In the US, the only commercially available TAVI system is the Edwards Sapien transcatheter aortic valve. For Marshall, who was not involved in the study, this is a major issue.
"As an American cardiologist, the US regulatory body, the Food and Drug Administration, is actually preventing some of these newer, and I think safer, devices being given to our patients," he toldheartwire. "It's a patient-centered issue, and the FDA is going so slowly on this. The newest device, the current commercially available Sapien device, is the only device available if you're not in a clinical trial, and it's a 22-F device. In Europe, you can get a 14-F device with the Sapien 3. I just think that for patient safety that's something the FDA would want to move along with a little faster. It's a little frustrating."
With the smaller sheaths, more patients would be suitable for TAVI, as Marshall said it's often the size of the iliac artery that prevents some of the older patients from getting the procedure. The larger the tube in a 90-year-old patient, the greater the chance of "iliac on a stick," a complication that occurs after an inadvertent iliac artery rupture and the intima is pulled or torn out. With the lack of small sheaths, and the subsequent risk posed to some patients, Marshall said he believes that these patients might resort to traveling to Europe or Canada for the newer aortic valves.
Marshall said the stroke rates in the present analysis are also in line with previous studies, noting that stroke typically occurs in patients if there is a problem with the valve, such as it being set too low, with a second valve needing to be implanted. In these elderly patients, excessive manipulation can lead to the increase risk of stroke.
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看：
【公告】动态版重启资讯翻译计划：我为人人，人人为我，共同提高 翻译时请把不确定的地方用红色字体标注，
寻找最近的翻译贴请查看：
点击进入
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
翻译三天未加分找 【版务】加分申诉点击
举报和合并加分专贴
【公告】版务管理之【举报和合并加分专贴】仅限于10分以下战友
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分。
原文链接：
http://www.medscape.com/viewarticle/777854
Equivalent Outcomes With Corevalve and Sapien Transcatheter Aortic Valves
MILAN, Italy — A head-to-head comparison of the CoreValve (Medtronic, Minneapolis, MN) and Sapien(Edwards, Irvine, CA) transcatheter aortic-valve implantation (TAVI) systems suggests there is no major difference between the two commercially available devices. At 30 days, there was no difference in the rate of all-cause mortality, cardiovascular mortality, MI, stroke, or device success, as well as no major difference in the rate of major vascular complications or life-threatening bleeding events.
In addition, there was no major difference in the rate of all-cause or cardiovascular mortality at one year.
The Medtronic CoreValve was associated with a higher rate of permanent pacemaker implantation, with 22.5% of patients requiring a pacemaker compared with 5.9% of patients treated with the Edwards Sapien/Sapien XT devices (hazard ratio [HR] 4.6; p<0.001).
"Overall, our results are encouraging, showing no difference between commercially available valve types except for a greater need for a [permanent pacemaker] PPM with the [Medtronic CoreValve], but clearly longer-term follow-up in the setting of an adequately powered randomized clinical trial is needed," state Dr Alaide Chieffo (San Raffaele Scientific Institute, Milan, Italy) and colleagues in their report, published online January 16, 2013 in the Journal of the American College of Cardiology.
Speaking with heart wire , Dr J Jeffrey Marshall (Northeast Georgia Heart Center, Gainesville), the president of the Society of Cardiovascular Angiography and Interventions, said the findings are in line with expectations, with clinicians well aware that the CoreValve, because of its self-expanding design, is associated with an increased risk of a need for a permanent pacemaker.
"Any time you have to have another procedure performed, it's not something you'd prefer, but it doesn't occur in a huge number of patients," said Marshall. "The need for a permanent pacemaker implantation is not something that's associated with a lot of complications in and of itself, so it's not that great an issue, although there is an extra cost, obviously."
Marshall noted that the incidence of aortic regurgitation was equal with both valves, a finding he said was reassuring, considering that previous trials suggested there might be differences between the valves in terms of aortic insufficiency following the procedure.
The PRAGMATIC Plus Initiative
The study, known as the PRAGMATIC Plus Initiative, included data from four experienced European centers. In total, 793 patients underwent TAVI, including 453 patients treated with the Medtronic CoreValve and 340 patients treated with the Edwards Sapien/Sapien XT devices. The 18-F sheath-compatible CoreValve was used in all but five cases (in these five cases the 21-F device was used) and the Sapien system used 22-/24-F sheaths until 2010, when the Sapien XT device offered the option of 18-/19-F sheath sizes. The average patient age was 82 years.
As noted, there was no significant difference in the 30-day and one-year clinical outcomes between the two TAVI systems. Because there were differences in the baseline characteristics of patients, the analysis was based on 204 propensity-score-matched patients.
Clinical Outcomes in the Propensity-Matched Patients
| Outcome | CoreValve, n=204 (%) | Sapien/Sapien XT, n=204 (%) | p |
| 30 d | |||
| All-cause mortality | 8.8 | 6.4 | 0.352 |
| Cardiac mortality | 6.9 | 6.4 | 0.842 |
| MI | 0.5 | 1.5 | 0.339 |
| Major stroke | 2.9 | 1.0 | 0.174 |
| Major vascular complications | 9.3 | 12.3 | 0.340 |
| Major bleeding | 18.1 | 22.1 | 0.324 |
| 1 y | |||
| All-cause mortality | 16.2 | 12.3 | 0.266 |
| Cardiac mortality | 8.3 | 7.4 | 0.713 |
| Moderate to severe aortic regurgitation | 5.2 | 2.8 | 0.302 |
In the US, the only commercially available TAVI system is the Edwards Sapien transcatheter aortic valve. For Marshall, who was not involved in the study, this is a major issue.
"As an American cardiologist, the US regulatory body, the Food and Drug Administration, is actually preventing some of these newer, and I think safer, devices being given to our patients," he toldheartwire. "It's a patient-centered issue, and the FDA is going so slowly on this. The newest device, the current commercially available Sapien device, is the only device available if you're not in a clinical trial, and it's a 22-F device. In Europe, you can get a 14-F device with the Sapien 3. I just think that for patient safety that's something the FDA would want to move along with a little faster. It's a little frustrating."
With the smaller sheaths, more patients would be suitable for TAVI, as Marshall said it's often the size of the iliac artery that prevents some of the older patients from getting the procedure. The larger the tube in a 90-year-old patient, the greater the chance of "iliac on a stick," a complication that occurs after an inadvertent iliac artery rupture and the intima is pulled or torn out. With the lack of small sheaths, and the subsequent risk posed to some patients, Marshall said he believes that these patients might resort to traveling to Europe or Canada for the newer aortic valves.
Marshall said the stroke rates in the present analysis are also in line with previous studies, noting that stroke typically occurs in patients if there is a problem with the valve, such as it being set too low, with a second valve needing to be implanted. In these elderly patients, excessive manipulation can lead to the increase risk of stroke.
最后编辑于 2022-10-09 · 浏览 1548
4 收藏点赞
